Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Mechanism of Action
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy.
Dosage Overview
Dose Range
2.5 mg – 15 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
12–52 weeks
Reconstitution
Typical Dosage (Research)
Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks.
Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects.
Considerations for Men & Women
Women: Same pregnancy contraindications as semaglutide — discontinue well before planned conception. Delayed gastric emptying may reduce oral contraceptive absorption; use non-oral backup contraception during dose escalation. May improve PCOS symptoms and fertility through weight loss.
Men: Weight loss benefits may improve obesity-related hypogonadism and testosterone levels. No sex-specific dose adjustments. Cardiovascular risk reduction benefits apply equally.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 2,500 mcg/ml
Volume to inject: 1.00 ml
Syringe units (U-100): 100.0 units
Pre-filled with Tirzepatide defaults. Adjust values as needed.
Side Effects & Risks
Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use.
Same thyroid cancer warnings as GLP-1 agonists. Risk of pancreatitis, gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas.
Who Uses Tirzepatide
Those seeking maximum weight loss efficacy, Type 2 diabetics, individuals who haven't achieved goals with GLP-1 monotherapy.
Frequently Asked Questions
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.